Summary
This paper reports exploratory subgroup analyses from the EV-302 phase III trial, which compared enfortumab vedotin plus pembrolizumab (EV+P) with platinum-based chemotherapy in 886 previously untreated patients with locally advanced or metastatic urothelial cancer. EV+P demonstrated consistent OS, PFS, and response rate benefits across all prespecified subgroups, including those with liver metastases, visceral metastases, and lymph node-only disease, mirroring the favourable intent-to-treat population outcomes reported previously.
UK applicability
These findings are relevant to UK oncology practice and NHS treatment guidelines for urothelial cancer, as they support EV+P as a potential standard-of-care first-line option across diverse patient populations. Adoption would require consideration of cost-effectiveness, manufacturing capacity, and integration with existing NHS cancer pathways.
Key measures
Progression-free survival (PFS), overall survival (OS), confirmed objective response rate, stratified by cisplatin eligibility status, presence/absence of liver metastases, and metastatic disease sites
Outcomes reported
The study evaluated progression-free survival (PFS), overall survival (OS), and confirmed objective response rates in patients with previously untreated locally advanced or metastatic urothelial carcinoma across prespecified subgroups defined by cisplatin eligibility, liver metastasis presence, and metastatic disease sites.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.